Arch Therapeutics, Inc. (ARTH)
| Market Cap | 13.80M |
| Revenue (ttm) | 9,391 |
| Net Income (ttm) | -5.64M |
| Shares Out | 237.07M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | 10.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 759,276 |
| Open | 0.0600 |
| Previous Close | 0.0605 |
| Day's Range | 0.0465 - 0.0600 |
| 52-Week Range | 0.0465 - 0.1400 |
| Beta | -0.48 |
| Analysts | Buy |
| Price Target | 3.06 (+5,157.7%) |
| Earnings Date | n/a |
About ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company ...
Analyst Forecast
According to 7 analysts, the average rating for ARTH stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 5,157.73% from the latest price.
News
Arch Therapeutics' Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Sessi...
World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound System World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS...
Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics' AC5® Advanced Wound System at 2022 Symposium on ...
Additional data covered a variety of specialties, including vascular surgery, plastic surgery, general surgery, and podiatry, to further support clinical efficacy of AC5® Advanced Wound System in acute,...
Arch Therapeutics' AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring
Additional case studies and key opinion leader discussion continues to support the broad potential of AC5® Advanced Wound System Additional case studies and key opinion leader discussion continues to su...
Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System
Strategic Alliance Positioned to Grow Sales Opportunities in Non-Government Hospital Channel Strategic Alliance Positioned to Grow Sales Opportunities in Non-Government Hospital Channel
Clinical Evaluation Finds Arch Therapeutics' AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds i...
AC5® Advanced Wound System demonstrated notable improvement in healing after only 3 to 6 applications—with only weekly clinic visits and reapplication AC5® Advanced Wound System demonstrated notable imp...
Arch Therapeutics Announces Appointment of Guy Fish to the Board
Brings Broad Industry Experience in Strategy and Execution Brings Broad Industry Experience in Strategy and Execution
Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound...
Significantly Expands Access to Include All Federal Government Agencies Significantly Expands Access to Include All Federal Government Agencies
Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5® Advanced Wound System
Arch Therapeutics Presents AC5® Advanced Wound System During Innovation Spotlight at 2021 Symposium on Advanced Wound...
Highlights Broad Clinical Benefits of AC5® Technology and Use in Managing Biofilm Infected Wounds Highlights Broad Clinical Benefits of AC5® Technology and Use in Managing Biofilm Infected Wounds
Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) Fall
AC5® Advanced Wound System Selected for Innovation Spotlight AC5® Advanced Wound System Selected for Innovation Spotlight
Arch Therapeutics Launches Experts in Wound Care Program
Key Opinion Leaders Share Insights on Advancing Wound Care Key Opinion Leaders Share Insights on Advancing Wound Care
Arch Therapeutics Provides Corporate Update
90-Day Report Card for Commercialization Effort
Arch Therapeutics to Present at the LD Micro Main Event
In-Person Presentation on October 13, 2021 In-Person Presentation on October 13, 2021
Arch Therapeutics Launches Coverage and Reimbursement Pilot
Critical Next Step in Commercialization Plan Commences Critical Next Step in Commercialization Plan Commences
Arch Therapeutics Announces Appointment of Larry Hicks to the Board
Brings deep industry experience to support commercialization plan Brings deep industry experience to support commercialization plan
Arch Therapeutics Partners with Lovell Government Services to Expand Distribution Capabilities
FRAMINGHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical device...
Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of Sales
Medical Industry Veteran with Proven Track Record to Drive Commercialization Effort
Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021
FRAMINGHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announc...
Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021
FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announc...
Arch Therapeutics' AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care ...
Honors for Highest Scoring Poster Abstract in Case Series/Study Category Confirms Commercialization Opportunities for AC5® Advanced Wound System Honors for Highest Scoring Poster Abstract in Case Series...
Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer
Company Prepares for Next Stage of Growth Company Prepares for Next Stage of Growth
Arch Therapeutics to Present AC5® Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC)
Additional case studies support the broad potential of AC5® Advanced Wound System in chronic and non-healing wounds Additional case studies support the broad potential of AC5® Advanced Wound System in c...
Arch Therapeutics Provides Corporate Update on Commercialization Efforts and Clinical Results
2021: Executing on Opportunities and Preparing for the Future 2021: Executing on Opportunities and Preparing for the Future
Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021
Management to provide corporate update on Dermal Sciences and BioSurgery Management to provide corporate update on Dermal Sciences and BioSurgery
Arch Therapeutics Announces Closing of $6.9 Million Private Placement
AC5® Advanced Wound System Commercialization Has Commenced AC5® Advanced Wound System Commercialization Has Commenced